{
  "docId": "019dd923-5ca1-7489-b638-e62bea0762fa",
  "docSlug": "78005f3a3554aa50",
  "documentTitle": "Refueling Innovation Engine Vaccines",
  "authorId": "McKinsey",
  "authorName": "McKinsey",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 19,
  "pageCount": 40,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "diagnosis",
  "function": "diagnose",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a bar chart to compare attrition rates and a list of specific industry examples to illustrate the point.",
  "elementsJson": [
    "headline_text",
    "bar_chart_horizontal",
    "callout_box",
    "paragraph"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-e62bea0762fa/19",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-e62bea0762fa",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-e62bea0762fa.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-e62bea0762fa#slide-19",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Attrition in Phase I drive by 3 factors: (1) Limited funding, especially for Phase II (2) biologic complexity of candidates (3) evidence that identifies unviable candidates earlier than for biologics",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-d3bb-700a-9da6-e5abde443b09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.55,
        "x": 0.02,
        "y": 0.135
      },
      "kind": "chart",
      "text": "Attrition rate of programs (2005-15)",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d80f5d45-784e-49e3-8bc1-9e06e8429541",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.38,
        "x": 0.6,
        "y": 0.135
      },
      "kind": "list",
      "text": "Examples of discontinued programs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "24622b24-1588-44e0-b09b-79565aa492fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Attrition rate: 48%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-d3bb-700a-9da6-eb4c9116bb6a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.96,
        "x": 0.02,
        "y": 0.84
      },
      "kind": "paragraph",
      "text": "Attrition in Phase I drive by 3 factors: (1) Limited funding, especially for Phase II (2) biologic complexity of candidates (3) evidence that identifies unviable candidates earlier than for biologics",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7baea9d8-3db5-48cb-8b01-aeb6df81fb84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.02,
        "y": 0.955
      },
      "kind": "source-note",
      "text": "SOURCE: Pharmaproject, McKinsey analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a54f294e-d2ea-46a3-8e34-13ea723928c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "Vaccine candidates are killed earlier than biologics, and we get fewer shots on goal",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1714a4f-cfd5-4da1-864c-c9cc7b7f760a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Attrition rate",
      "numberRaw": "48%",
      "numberKind": "percent",
      "actionTitle": "Vaccine candidates are killed earlier than biologics, and we get fewer shots on goal",
      "calloutText": "Attrition in Phase I drive by 3 factors: (1) Limited funding, especially for Phase II (2) biologic complexity of candidates (3) evidence that identifies unviable candidates earlier than for biologics",
      "numberScale": null,
      "numberValue": 48,
      "metricFamily": "rate_catchall",
      "numberCurrency": null
    }
  ],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "30289dba-55bd-4362-8511-80da8e2c15f4",
      "evidence": "chart/bar-grouped: Attrition rate of programs (2005-15)",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "f9c4c201-1132-446a-ab51-f4f7ca0f8b84",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The deck highlights the challenges to innovation, including declining profitability, increasing time to market, and manufacturing challenges.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}